{
    "title": "Estimating treatment effects from single-arm trials via latent-variable modeling",
    "abstract": "arXiv:2311.03002v2 Announce Type: replace  Abstract: Randomized controlled trials (RCTs) are the accepted standard for treatment effect estimation but they can be infeasible due to ethical reasons and prohibitive costs. Single-arm trials, where all patients belong to the treatment group, can be a viable alternative but require access to an external control group. We propose an identifiable deep latent-variable model for this scenario that can also account for missing covariate observations by modeling their structured missingness patterns. Our method uses amortized variational inference to learn both group-specific and identifiable shared latent representations, which can subsequently be used for {\\em (i)} patient matching if treatment outcomes are not available for the treatment group, or for {\\em (ii)} direct treatment effect estimation assuming outcomes are available for both groups. We evaluate the model on a public benchmark as well as on a data set consisting of a published RCT s",
    "link": "https://arxiv.org/abs/2311.03002",
    "context": "Title: Estimating treatment effects from single-arm trials via latent-variable modeling\nAbstract: arXiv:2311.03002v2 Announce Type: replace  Abstract: Randomized controlled trials (RCTs) are the accepted standard for treatment effect estimation but they can be infeasible due to ethical reasons and prohibitive costs. Single-arm trials, where all patients belong to the treatment group, can be a viable alternative but require access to an external control group. We propose an identifiable deep latent-variable model for this scenario that can also account for missing covariate observations by modeling their structured missingness patterns. Our method uses amortized variational inference to learn both group-specific and identifiable shared latent representations, which can subsequently be used for {\\em (i)} patient matching if treatment outcomes are not available for the treatment group, or for {\\em (ii)} direct treatment effect estimation assuming outcomes are available for both groups. We evaluate the model on a public benchmark as well as on a data set consisting of a published RCT s",
    "path": "papers/23/11/2311.03002.json",
    "total_tokens": 871,
    "translated_title": "通过潜变量建模从单臂试验中估计治疗效果",
    "translated_abstract": "随机对照试验（RCTs）被接受为治疗效果估计的标准，但由于伦理原因和成本过高而不可行。单臂试验，所有患者属于治疗组，可能是一个可行的替代方案，但需要访问外部对照组。我们提出了一个可识别的深度潜变量模型，可以用于这种情况，并且还可以通过建模结构化缺失模式来考虑缺失的协变量观察。我们的方法使用摊销变分推断来学习既特定于组又可识别的共享潜在表示，随后可用于（i）患者匹配，如果治疗组的治疗结果不可用，或用于（ii）假定两组均有结果可用的直接治疗效果估计。我们在一个公共基准和一个由已发表的RCT组成的数据集上评估了该模型。",
    "tldr": "通过深度潜变量模型和摊销变分推断，我们提出了一种可用于单臂试验的治疗效果估计方法，可以处理缺失的协变量观察，实现患者匹配或直接治疗效果估计。"
}